

## Humber Area Prescribing Committee

<b>Date / Time</b>	6 <sup>th</sup> March 2024 13:00-15:00
<b>Venue</b>	MS Teams
<b>Chair</b>	Dr Sergio Raise
<b>Notes / Action Points</b>	Luke Storr – Senior Pharmacy Technician, HUTH
<b>Quorate: Yes / No</b>	No – JM to send items to NP outside the meeting
<b>Attendance</b>	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Simon Priestley- Chief Pharmacist, NLAG (SP) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK) Daniel Newsome- Principal Pharmacist RDTC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Joanne Goode – Chief Pharmacist – HUTH (JG) Dr Pratik Basu- GP- The Birches medical practice (PB) Dr Rolan Schreiber, Medical Secretary LMC (RSc) Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Alberto Ortiz-Moya – Principal Pharmacist MH & LD Services (AO) Anna Grocholewska-Mhamdi – Lead Clinical Pharmacist – Navigo (AG)
<b>Apologies</b>	Narayana Pothina- Consultant in adult medicine, NLAG (NP) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS)

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.03.01	Apologies	Noted above			
2024.03.02	Declarations of interest	None			
2024.03.03	Minutes of previous meeting	Accepted as true record			
2024.03.04	Action Tracker	<p><b>Prescription requests in primary care</b> –action transferred from NLAPC to Humber APC</p> <p>To produce joint document detailing supply details from secondary to primary care for all providers within Humber region</p> <p>To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies)</p> <p>June 2023: In progress</p> <p>July 2023: In progress</p> <p>August 2023: Received info from CHCP/HFT, JM to prepare new document.</p> <p>September 2023: In progress</p> <p>October 2023: In progress</p> <p>November 2023: In progress</p> <p>December 2023: In progress</p> <p>March 2024: In progress</p> <p><b>Outstanding actions from NLAPC</b></p> <p>Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)</p> <p>JM to provide RS information on number of patients in NEL/NL</p> <p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafinil still waiting on NL, JM to review mycophenolate for July guideline group</p>	<p>Ongoing</p> <p>Ongoing</p>	<p>AK/JM</p> <p>JM/RS</p>	<p>4/24</p> <p>4/24</p>

		<p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group  August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group  September 2023 update: For September guideline group  October 2023 update: For November Guideline group  November 2023 update: For November Guideline group  December 2023 update: For January or March guideline group – to check against York mycophenolate.  February 2024 update: reviewed against York SCF and contacted neuromuscular lead with national SCF. For March guideline group</p> <p><b>Outstanding actions from HERPC</b></p> <p>Renal repatriation:  November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time.  December update – Not met with renal yet.  March update – Updating business case.  May update – to meet with NHSE  August update – not yet met with NHSE  September update: not yet met with NHSE  October update: not yet met with NHSE  November update: not yet met with NHSE  December update: meeting arranged with NHSE  February update: meeting arranged and business case in progress</p> <p><b>Blueteq</b></p> <p>Non-compliance to NICE guidance in acute trusts and financial impact  June update: JM to submit ustekinumab report in gastroenterology HUTH when approved  JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved  July update: JM to update next time.  August update: no further update, infliximab audit in HUTH started  September update: HUTH audits still ongoing  October update: HUTH audits still ongoing  November update: HUTH audits still ongoing</p>	Ongoing	JM	4/24
		<p><b>Blueteq</b></p> <p>Non-compliance to NICE guidance in acute trusts and financial impact  June update: JM to submit ustekinumab report in gastroenterology HUTH when approved  JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved  July update: JM to update next time.  August update: no further update, infliximab audit in HUTH started  September update: HUTH audits still ongoing  October update: HUTH audits still ongoing  November update: HUTH audits still ongoing</p>	Ongoing	JM	4/24

		<p>December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch.</p> <p>February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance.</p> <p>March 2024 update: Infliximab paper due to presented at April D&amp;TC</p> <p><b>Outstanding actions from HERPC:</b></p> <p>Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&amp;TC action tracker. To discuss at September D&amp;TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper.</p> <p>September update: September D&amp;TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> <p>November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch.</p> <p>December update: ongoing</p> <p>February 2024 update: February 2024 update: JG to follow up with Dr Ogumbambi</p> <p>March 2024 update: JG raised at HUTH D&amp;TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi.</p> <p><b>Ratification of guidelines and SCFs:</b></p> <p>Sick Day Guidance in T2DM</p> <p>JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team</p> <p>December 2023 – ongoing</p> <p>February 2024 – ongoing</p> <p><b>Ratification of guidelines and SCFs:</b></p> <p>Amiodarone SCF</p> <p>JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH</p> <p>September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites.</p>	Ongoing	JM	6/24
		<p><b>Ratification of guidelines and SCFs:</b></p> <p>Sick Day Guidance in T2DM</p> <p>JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team</p> <p>December 2023 – ongoing</p> <p>February 2024 – ongoing</p>	Ongoing	JM	2/24
		<p><b>Ratification of guidelines and SCFs:</b></p> <p>Amiodarone SCF</p> <p>JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH</p> <p>September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites.</p>	Ongoing	JM	4/24

		<p>October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG.</p> <p>November 2023 – to be discussed at next cardiology governance</p> <p>December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review</p> <p>February 2024 update: ongoing</p> <p>March 2024 update: JM to send updated SCF to CS for review.</p> <p><b>Feedback from Integrated Medicines Optimisation Committee</b></p> <p>Sodium valproate prevent compliance</p> <p>December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms.</p> <p>March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG.</p> <p><b>Ratification of guidelines and SCFs – JIC medication leaflet</b></p> <p>AK to send to St Andrews Hospice GP team.</p> <p>November update – contacted clinical directors and they were happy with content. Given a contact for logos and awaiting response</p> <p>December 2023 – Now have all logos and contact. JM to tidy up and publish on website.</p> <p>March 2024 – to publish on website</p> <p><b>Ratification of joint formulary – chapter 6</b></p> <p>To update netFormulary and remove HERPC chapter</p> <p>December update: ongoing</p> <p>March 2024 update: drugs all completed just links to update</p> <p><b>Work plans</b></p> <p>To add review of guidance priority to guideline group meeting</p> <p><b>Work plans</b></p> <p>To add RDTSC SCF to guideline/SCF group to review against local SCFs when published</p> <p><b>Ratification of guidelines and SCFs</b></p> <p>To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance</p> <p><b>Ratification of guidelines and SCFs</b></p> <p>To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded</p> <p><b>Ratification of joint formulary – chapter 12</b></p> <p>To update netFormulary – action complete</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p>	<p>JM/KMc</p> <p>AK/JM</p> <p>JM/LS/AK</p> <p>LS</p> <p>LS</p> <p>JM</p> <p>JM</p> <p>LS/JM/AK</p>	<p>4/24</p> <p>4/24</p> <p>4/24</p> <p>3/24</p> <p>6/24</p> <p>4/24</p> <p>4/24</p> <p>6/24</p>
--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------

		<p><b>RTDC updates</b> To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920)</p> <p><b>Traffic Light Status</b> To update Humber APC formulary</p> <p><b>Traffic Light Status</b> To update HERPC formulary where needed</p> <p><b>Traffic Light Status</b> To update HERPC red list</p> <p><b>Ratification of guidelines and SCFs</b> Upload relevant guidance (IBD pathway, prescribing anticoagulants, migraine and cluster headache)</p> <p><b>RTDC updates</b> To update formulary/red list</p> <p><b>Correspondence received</b> To update chapter 5 with malaria medicines as per national guidance</p>	Ongoing	JM/OA	2/24
			Action complete	JM/AK/LS	3/24
			Action complete	JM/LS	3/24
			Action complete	JM	3/24
			Action complete	JM	3/24
			Action complete	JM	3/24
			Action complete	JM	3/24
			Action complete	JM/AK/LS	3/24
2024.03.05	Traffic Light Status	<p>Doublebase ONCE daily- Meeting with dermatology as requested feedback on item and review all emollient options. Slynd- Proposed as AMBER 2 Anastrozole- Proposed as AMBER 1 for Lursidone- proposed as AMBER 2</p>	Update formularies/red list	JM/LS/AK	
2024.03.06	Feedback from Integrated Medicines Optimisation Committee	<p>LB prepared a stakeholders report from IPMOC which was presented.</p> <ul style="list-style-type: none"> <li>• The DOAC proposal was endorsed</li> <li>• The differences between approach to TAs in both APCs and individual differences between trusts was discussed.</li> <li>• The RTDC shared care were recommended for use when reviewing SCFs.</li> <li>• The low molecular weight heparin switches and use of biosimilar ranibuzimab was also discussed.</li> </ul>	Noted		

2024.03.07	Work plans	<ul style="list-style-type: none"> <li>a) Joint formulary alignment</li> <li>b) Shared care frameworks</li> <li>c) Guidelines</li> </ul>	Ongoing for information only		
2024.03.08	Ratification of guidelines and SCFs	<ul style="list-style-type: none"> <li>a) Orthostatic Hypotension – updated guidance with definition of orthostatic hypotension update against NICE and Royal College of Physicians guidance.</li> <li>b) Corticosteroid inhalers – document produced to support the ICB asthma guidance.</li> <li>c) Dementia SCF – JM to e-mail issues and proposal to members for discussion outside meeting.</li> <li>d) ADHD NEL – update due to change of service</li> <li>e) Heart Failure - deferred</li> </ul>	<ul style="list-style-type: none"> <li>a) Approved</li> <li>b) Approved</li> <li>c) Deferred</li> <li>d) Approved</li> <li>e) Deferred</li> </ul>	JM	3/24
2024.03.09	Ratification of joint formulary	<ul style="list-style-type: none"> <li>• Chapter 3</li> </ul>	Deferred to next meeting		
2024.03.10	RTDC updates	<ul style="list-style-type: none"> <li>• Jan 24</li> </ul>	Update formulary/red list	JM/LS/AK	3/24
2024.03.11	Minutes from subcommittees	<ul style="list-style-type: none"> <li>a) Joint formulary subcommittee (Dec 23)</li> <li>b) Guideline subcommittee (Nil)</li> </ul>	Attached for info only		
2024.03.12	Additional minutes for information	<ul style="list-style-type: none"> <li>a) HUTH D&amp;TC (Jan 24)</li> <li>b) HFT DTG (Nil)</li> <li>c) NLAG M&amp;T (Nil)</li> <li>d) NYY APC (Dec 23)</li> </ul>	Attached for info only		
2024.03.13	Correspondence received	Nil this month			
2024.03.14	AOB	<ul style="list-style-type: none"> <li>• Fluticasone nasal sprays- current supply issue with Avamys®, approval to use fluticasone propionate as alternate while issue is ongoing</li> <li>• Cyclizine- point raised by SR, cyclizine injection is currently RED on formulary. Approved to update the status to GREEN for palliative care use (for patients who cannot use haloperidol). JM also looking at palliative care section of formulary – York and Scarborough formulary has one already on their formulary.</li> </ul>			
2024.03.15	Date of next meeting	3 <sup>rd</sup> April 2024 13.00 – 15.00 Teams			